al-Hosani H, Salah M, Saade D, Osman H, al-Zahid J
Central Department of Maternal and Child Health, Ministry of Health, Abu-Dhabi, United Arab Emirates.
East Mediterr Health J. 2003 May;9(3):324-32.
To evaluate the United Arab Emirate National Newborn Screening Programme we compared coverage, timeliness of programme indicators (age at sampling, recall and treatment initiation, timing of specimen delivery and laboratory results) and specimen quality with international standards. Recall rate, sensitivity, specificity, positive predictive values and relative incidence rates for phenylketonuria (PKU) and congenital hypothyroidism (CH) were calculated. Investigations for hypothyroidism included thyroid function studies (T3, T4, fT4 and TSH), technetium-99m thyroid scan when possible and thyroglobulin and thyroid antibodies when indicated. PKU investigations included plasma amino acids and measurement of biopterin defects. In the 6 years before December 2000, 138,718 neonates were screened. Relative incidences for CH and for classic PKU were 1:1570 and 1:20,050 respectively.
为评估阿拉伯联合酋长国国家新生儿筛查项目，我们将该项目的覆盖率、项目指标的及时性（采样年龄、召回和开始治疗的时间、样本送达时间及实验室结果）以及样本质量与国际标准进行了比较。计算了苯丙酮尿症（PKU）和先天性甲状腺功能减退症（CH）的召回率、敏感性、特异性、阳性预测值及相对发病率。甲状腺功能减退症的检查包括甲状腺功能研究（T3、T4、游离T4和促甲状腺激素）、可能时的锝-99m甲状腺扫描以及必要时的甲状腺球蛋白和甲状腺抗体检测。PKU的检查包括血浆氨基酸和生物蝶呤缺陷检测。在2000年12月之前的6年里，对138,718名新生儿进行了筛查。CH和典型PKU的相对发病率分别为1:1570和1:20,050。
